Feature | September 29, 2010| Dave Fornell

PARTNER Trial Shows Excellent Outcomes For Transcatheter Aortic Valve

Experts say TAVI should replace standard care for sickest patients

Transcatheter valve therapies were among the hottest topics at the 2010 Transcatheter Cardiovascular Therapeutics (TCT) symposium and the key presentation was the very positive first release of data from the U.S. PARTNER trial. The trial results are widely expected to open the door to a major transition away from surgical to transcatheter aortic valve repair in the coming years.

The trial compared patients with severe aortic stenosis who were not suitable candidates for surgery, who were randomized between transcatheter aortic valve implantation (TAVI) using the Sapien THV valve, as compared with the standard therapy of balloon aortic valvuloplasty. The PARTNER trial showed a significantly reduced rate (54 percent) of death from all causes and rehospitalization using TAVI.

Presenting the data was Martin Leon, M.D., associate director of the Center for Interventional Vascular Therapy, New York-Presbyterian Hospital/Columbia University Medical Center and chairman of the Cardiovascular Research Foundation. He explained the results of PARTNER’s cohort B, which included 358 patients who were considered high-risk surgical patients and turned down for surgical valve repair. Of these patients, 179 were treated with TAVI. Leon said the data show TAVI was superior to standard therapy, markedly reducing death after one year. It significantly reduced the rates of death from cardiovascular causes and repeat hospitalization.

“Not only did the patients live longer, they felt better,” Leon said.

At 30 days, there was a major statistical difference in the six-minute walking test results between TAVI and standard care patients. At one year, Leon said 75 percent of patients with New York Heart Association Class III and IV heart failure were reduced to class I and II levels. Ninety percent of TAVI patients also had no or only minor aortic valve regurgitation.

“We believe that TAVI should be the new standard of care for patients who have aortic valve stenosis and are not suitable candidates for surgery,” Leon said.

He said a major reduction in deaths and disease was accomplished with a new procedure being performed by inexperienced operators, which he thought was astounding.

“We also learned standard therapy, in almost 84 percent of patients, did not alter the abysmal natural history of aortic stenosis,” Leon explained.

Despite the excellent results, Leon said TAVI patients did have much higher rates of major vascular events (16.2 percent vs. 1.2 percent) and major bleeding (16.8 percent vs. 3.8 percent) and stroke due to the implant procedures.

“It’s a remarkable result,” said Ian Meredith, MBBS, Ph.D., Monash University and executive director of the Monash Cardiovascular Research Centre, Melbourne, Australia. “To see these really sick patients doing so well so early in the trial is very promising.”

He hopes the stroke rate can be lowered, possibly with the use of embolic protection devices.

“It is an overwhelming trial for us,” said Jeffrey Popma, M.D., Beth Israel Deaconess Medical Center, Boston. “What I am most struck by in this trial is how poorly the standard-of-care patients did.”

He cited the 50 percent mortality rate for patients in the standard care arm of cohort B. He and many other physicians question whether it will be ethical in the future to randomize patients to standard therapy with such poor outcomes.

The study data was published in The New England Journal of Medicine on the eve of the TCT presentation.

“Without exciting, new minimally invasive treatment options like TAVI, people with severe aortic stenosis will continue to have few to no treatment options and will die from their disease,” said Christopher White, M.D., FSCAI, chairman, department of cardiology, and director of the Ochsner Heart and Vascular Institute, Ochsner Medical Center in New Orleans, and president-elect of the Society for Cardiovascular Angiography and Interventions (SCAI). “These results are very encouraging and suggest TAVI is an effective treatment option for severe aortic stenosis in patients who cannot have surgery.”

He said the first angioplasty in 1977 provided a new, minimally invasive way to treat heart attacks that today has resulted in millions of lives saved. He said TAVI may be in the same class and may provide a new frontier in treating these patients.

For more information: www.nejm.org

Related Content

News | Cardiac Diagnostics| February 17, 2017
Levels of a protein in the blood associated with heart disease are also linked to early-stage brain damage, according...
Edwards Intuity Elite sutureless aortic valve, first implants in Connecticut, WCHN, Western Connecticut Health Network
News | Cardiovascular Surgery| February 16, 2017
Western Connecticut Health Network (WCHN) cardiothoracic surgeons Cary Passik, M.D., and Robert Gallagher, M.D., were...
Mercator MedSystems, DANCE trial data, ISET, LINC, Bullfrog Micro-Infusion Device
News | Peripheral Arterial Disease (PAD)| February 15, 2017
Mercator MedSystems announced that the national co-principal investigators of the company’s DANCE trial each presented...
heart team, hybird OR, structural heart team

The heart team approach was first used on a large scale in the CoreValve and Sapien TAVR trials and helped lead to excellent outcomes in high-risk patients.

Feature | Hybrid OR| February 15, 2017 | Dave Fornell
In the current era of healthcare reform and the push toward evidence-based medicine to both lower costs and improve p
Medtronic, IDE approval, IN.PACT Admiral drug-coated balloon, DCB, end-stage renal disease
News | Drug-Eluting Balloons| February 08, 2017
Medtronic plc announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug Administration...
CSI, LIBERTY 360 Study, ISET 2017, six-month data, lower extremity PAD
News | Atherectomy Devices| February 08, 2017
February 8, 2017 — Cardiovascular Systems (CSI) presented six-month data from its LIBERTY 360° post-market study in a
Penn Medicine, heart failure causes, YAP and TAZ proteins, Journal of Clinical Investigation study
News | Heart Failure| February 07, 2017
February 7, 2017 — Of the more than 700,000 Americans who suffer a heart attack each year, about a quarter go on to d
Avinger, VISION Study, two-year outcomes, LINC, Lumivascular technology, Pantheris, OCT-guided atherectomy
News | Atherectomy Devices| February 03, 2017
Avinger Inc. recently announced positive two-year clinical data from the pivotal VISION study of the company’s...
Texas Heart Institute, ischemic heart failure, adult stem cell therapy, CONCERT-HF clinical trial
News | Stem Cell Therapies| February 03, 2017
Physicians and researchers at Texas Heart Institute are recruiting patients who suffer from heart failure to...
Ohio State, Wexner Medical Center, keeping human hearts alive, track abnormal beats, reanimate, Vadim Fedorov

Part of a donated human heart is reanimated and recorded with four high-definition optic cameras in a laboratory at The Ohio State University Wexner Medical Center. Researchers keep the heart tissue alive to look for the causes of irregular heartbeats in cases of persistent atrial fibrillation. Image courtesy of The Ohio State University Wexner Medical Center.

News | EP Lab| February 01, 2017
Researchers have developed a technique that allows them to revive parts of human hearts in the laboratory for up to 12...
Overlay Init